CloudMD Launches Addiction Support Program Focused on Early Intervention and Relapse
December 09 2020 - 6:30AM
CloudMD Software & Services Inc. (TSXV: DOC, OTCQB:
DOCRF, Frankfurt: 6PH) (the “
Company” or
“
CloudMD”), a telehealth company revolutionizing
the delivery of healthcare to patients, is excited to announce that
it has launched an addiction support program through its mental
health solution, Snapclarity Inc. (“
Snapclarity”)
and robust educational library, iMD Global Health Inc.
(“
iMD”) which focuses on providing support and
resources for early intervention and relapse.
The COVID pandemic has highlighted a significant
increase in health issues due to addiction and substance use
disorder. According to the Journal of American Medical Association
(JAMA), there is accumulating evidence that indicates a “second
wave” is building caused by rising rates of mental health and
substance use disorders. This imminent mental health surge will
bring further challenges for individuals, families, and communities
including increased deaths from suicide and drug overdoses. In
Canada, 25% of Canadians aged 35-54 staying at home indicate that
their alcohol consumption has increased(1). Substance abuse and
addiction was a concern before the pandemic, with approximately 21%
of the total population experiencing addiction at some point in
their lifetime(2).
There are many resources supporting individuals
with anxiety, depression and other mental health conditions but few
have a specialized treatment for early identification and
management of substance use disorders. This new program
will include resources for early intervention and relapse to
continue to support those with substance use issues. Through
its proprietary app, Snapclarity offers mental health assessments
and counselling to empower individuals in treatment and recovery,
when integrated with iMD’s robust library of resources and
education tools, the program will provide a comprehensive care plan
that supports individuals on their mental health journey.
Karen Adams, Global Head of Enterprise
Health Solutions commented, “We’ve developed this program
recognizing that in most cases, individuals cannot address
substance issues through traditional cognitive behavioural therapy
programs or short-term care models. We are seeing an increasing
trend of people concerned with habits being formed relating to
alcohol use during COVID. We want to provide people an early
intervention program to assist in what is sure to become a concern
post COVID.”
Alongside the proprietary assessment tool that
screens risk levels for a wide range and number of mental health
concerns, the platform has introduced a specialized detailed
substance use assessment to further understand the needs of the
participants. Through this assessment, the platform will be
able to identify individuals who are suffering from substance use
disorder or who are more likely to benefit from a preventative
care plan. After the initial triaging process, patients will be
connected with counsellors and therapists trained in addiction and
substance use disorder. The healthcare professionals will be able
to provide ongoing support, treatment plans and additional
educational tools and resources to the patients. Longer term, the
program provides aftercare support and includes in-app messaging
for reinforcement, continued access to therapists, online recovery
groups and individual recovery plans.
Dr. Essam Hamza, CEO of CloudMD
commented, “We realize the immediate demand for increased mental
health support including addiction and substance use disorders. Our
team-based, holistic approach to healthcare is focused on
delivering unique care plans specific to each individual through
assessment and navigation. The combination of Snapclarity’s
revolutionary mental health platform, and iMD’s robust educational
library, is just one example of how we can integrate our healthcare
solutions to build industry-leading platforms and programs to
address whole-person care through multiple modalities and create
individualized plans for treatment, support and recovery.”
About Snapclarity
Snapclarity is a pioneer through an on demand
digital platform that provides an assessment for mental health
disorders resulting in a personalized care plan, access to online
resources, a clinical health care team and the ability to match to
the right therapists. To learn more about Snapclarity please visit:
www.snapclarity.com and to download the individual app please visit
the Apple App Store and/or the Google Play Store. Snapclarity is a
CloudMD Company.
About iMD
iMD Health Global is a Toronto-based ehealth
software development company, focused on innovating healthcare
education. Since 2010, iMD has grown into Canada’s largest digital
patient engagement platform. Centered “At The Point of Care”®,
healthcare professionals use iMD’s cloud-based platform (in clinic
or virtual consults) to engage with their patients at a deeper
level and optimize knowledge transfer surrounding a patient’s
condition and treatment plan. This is done through the seamless
integration of over 80,000 images, booklets, and video
resources (covering 2,100 medical topics), into an
award-winning user interface that makes patient education both
efficient and effective. The iMD platform is utilized by doctors,
nurses and pharmacists in clinics, hospitals, pharmacies, infusion
clinics and in-home care settings. Learn more
at imdhealth.com and app.imdhealth.com. iMD is a
CloudMD Company.
About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare
by providing a patient centric approach, with an emphasis on
continuity of care. The Company offers SAAS based health technology
solutions to healthcare providers across North America and has
developed proprietary technology that delivers quality healthcare
through a holistic offering including hybrid primary care
clinics, specialist care, telemedicine, mental health support,
educational resources and artificial intelligence (AI). CloudMD
currently services a combined ecosystem of over 500
clinics, almost 4000 licensed practitioners and 8 million patient
charts across North America. For more information visit:
www.cloudmd.ca.
ON BEHALF OF THE BOARD OF
DIRECTORS “Dr. Essam
Hamza, MD"Chief Executive Officer
FOR ADDITIONAL INFORMATION CONTACT:
Julia BeckerVP, Investor
Relations julia@cloudmd.ca
Media Contact:
joanne@getfreshpr.com
Sales: info@cloudmd.ca
Forward Looking Statements
This news release contains forward-looking
statements that are based on CloudMD’s expectations, estimates and
projections regarding its business and the economic environment in
which it operates, including with respect to its business plans.
Although CloudMD believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to control or
predict. Therefore, actual outcomes and results may differ
materially from those expressed in these forward-looking statements
and readers should not place undue reliance on such statements.
These forward-looking statements speak only as of the date on which
they are made, and CloudMD undertakes no obligation to update them
publicly to reflect new information or the occurrence of future
events or circumstances, unless otherwise required to do so by
law.
The TSX Venture Exchange does not accept
responsibility for the adequacy or accuracy of this release.
-
https://www.ccsa.ca/sites/default/files/2020-04/CCSA-NANOS-Alcohol-Consumption-During-COVID-19-Report-2020-en.pdf
-
https://ontario.cmha.ca/addiction-and-substance-use-and-addiction/
CloudMD Software & Servi... (TSXV:DOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
CloudMD Software & Servi... (TSXV:DOC)
Historical Stock Chart
From Apr 2023 to Apr 2024